Kidney disease, a silent threat, often goes unnoticed due to its subtle symptoms that mimic other common conditions.

Regeneron (REGN) stock in focus as the company surpasses Street's Q2 projections with strong growth in high-dose Eylea, ...

There has been an alarming rise in cases of type 2 diabetes among Gen Z, causing major concern. According to experts, apart ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, Regeneron expects “to receive favorable action” on these applications, CEO ...